Sequana Medical NVSTU:2SE 34 EV-to-FCF is -4.63 as of Jul. 05, 2026. GuruFocus rates STU:2SE with a GF Score™ of 34/100 and a GF Value™ of €0.19 (Significantly Overvalued). The stock has 12 warning signs investors should review. Among 417 Medical Devices & Instruments companies, Sequana Medical NV ranks worse than 239807.91% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sequana Medical NV's Enterprise Value is €81.85 Mil.
Sequana Medical NV's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was €-17.69 Mil. Therefore, Sequana Medical NV's EV-to-FCF for today is -4.63.
The historical rank and industry rank for Sequana Medical NV's EV-to-FCF or its related term are showing as below:
STU:2SE'
s EV-to-FCF Range Over the Past 10 Years
Min: -11.4 Med: -4.08 Max: -1.04
Current: -4.63
During the past 11 years, the highest EV-to-FCF of Sequana Medical NV was -1.04. The lowest was -11.40. And the median was -4.08.
STU:2SE's EV-to-FCF is ranked worse than 100% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 23.4
vs STU:2SE: -4.63
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sequana Medical NV (STU:2SE) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sequana Medical NV's PE Ratio (TTM) for today is calculated as:
Sequana Medical NV's share price for today is €0.511.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sequana Medical NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was €-1.230.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sequana Medical NV EV-to-FCF Related Terms
Sequana Medical NV EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sequana Medical NV's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sequana Medical NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sequana Medical NV EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sequana Medical NV's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sequana Medical NV's EV-to-FCF falls into.
Sequana Medical NV's current Enterprise Value is €81.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sequana Medical NV's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was €-17.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sequana Medical NV (STU:2SE) has a EV-to-FCF of -4.63 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sequana Medical NV and its competitors. According to the industry distribution chart, Sequana Medical NV ranks #999999 out of 417 companies in the Medical Devices & Instruments industry.
Is Sequana Medical NV's EV-to-FCF too high?
Sequana Medical NV's current EV-to-FCF is -4.63. Based on the distribution chart, Sequana Medical NV ranks #999999 out of 417 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sequana Medical NV has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sequana Medical NV's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sequana Medical NV ranks #999999 out of 417 companies for EV-to-FCF. This places Sequana Medical NV in the lower half of its industry. The industry median EV-to-FCF is 23.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.40, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sequana Medical NV and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sequana Medical NV's current EV-to-FCF is -4.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sequana Medical NV stock overvalued right now?
Based on GuruFocus' analysis, Sequana Medical NV (STU:2SE) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 168.9% above its estimated fair value. The current EV-to-FCF is -4.63. Sequana Medical NV's overall GF Score™ is 34/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sequana Medical NV (STU:2SE), the current EV-to-FCF is -4.63 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sequana Medical NV (STU:2SE) Overvalued in 2026?
Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued.
The current stock price of €0.51 is trading 168.9% above its estimated GF Value™ of €0.19.
GuruFocus considers Sequana Medical NV to be Significantly Overvalued.
Key valuation signals for STU:2SE:
EV-to-FCF: -4.63
GF Value™: €0.19 vs. price of €0.51 (168.9% above fair value)
No single metric tells the full story. See the STU:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
34GF Score
Get the complete analysis for STU:2SE
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2SE has been successfully added to your 
